Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
Business Wire•15/10/2026•08:00 ET
0
Key Highlights
- ➤Xeris (XERS) announced data presentations for Gvoke, Recorlev, and XP-8121.
- ➤Gvoke data highlights gaps between glucagon guideline awareness and prescribing practices.
- ➤Recorlev case study linked cortisol normalization with improved cardiometabolic parameters.
- ➤TriNetX analysis will characterize hypothyroidism using linked levothyroxine and TSH data.
- ➤XP-8121 is a Phase 3-ready, once-weekly hypothyroidism injection.
Expert Statements
Anh Nguyen, Chief Medical Officer of Xeris Biopharma
“These presentations reflect the breadth and depth of our scientific work and collaborations across endocrinology, as well as our commitment to advancing care at every stage, from established therapies to emerging treatment approaches.”
Anh Nguyen, Chief Medical Officer of Xeris Biopharma
“By sharing real-world experience with Recorlev and new research on Gvoke, we continue to build the evidence supporting therapies patients rely on today. At the same time, our TriNetX analysis expands our understanding of real-world biochemical control among patients with hypothyroidism treated with oral levothyroxine.”
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
Clinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinology, including the treatments for Severe Hypoglycemia, Cushing's Syndrome, and Hypothyroidism
Get started
Create a free account to read the full story.